Credit Suisse says Allergan's drug pipeline is 'underappreciated'
July 25, 2016 at 13:08 PM EDT
Credit Suisse analysts initiated shares of Allergan at an "outperform" rating, saying its diversified drug pipeline is underappreciated by investors.
